'Good' cholesterol function as important as its levels
- Date:
- June 23, 2011
- Source:
- Journal of Clinical Investigation
- Summary:
- Many studies have indicated that therapeutics that increase levels of "good" cholesterol (HDL cholesterol) could be clinically useful for the treatment of coronary artery disease -- a disease of the major arterial blood vessels that is one of the major causes of heart attack and stroke. However, such therapies have not yielded clear-cut decreases in disease. New research now indicates why the beneficial effects of HDL are not related simply to its abundance.
- Share:
High levels of "good" cholesterol (HDL cholesterol) are associated with a decreased risk of coronary artery disease (CAD) -- a disease of the major arterial blood vessels that is one of the major causes of heart attack and stroke. This suggests that therapeutics that increase HDL levels could be clinically useful. However, such therapies have not yielded clear-cut decreases in disease, indicating that the beneficial effects of HDL are likely not related simply to its abundance.
More evidence to support this notion has now been provided by a team of researchers, led by Ulf Landmesser, at the University of Zurich, Switzerland, who found that HDL from patients with (CAD) had different effects on cells lining blood vessels than did HDL from healthy individuals. In particular, the HDL from patients with CAD was found to lack anti-inflammatory effects on blood vessel-lining cells and could not stimulate repair of the blood vessel lining.
The research is published in the Journal of Clinical Investigation.
As noted by the team and, in an accompanying commentary, Philip Shaul and Chieko Mineo, at The University of Texas Southwestern Medical Center, Dallas, these data indicate that if the protective potential of HDL is to be harnessed, its biological functions as well as its abundance must be considered.
Story Source:
Materials provided by Journal of Clinical Investigation. Note: Content may be edited for style and length.
Journal References:
- Christian Besler, Kathrin Heinrich, Lucia Rohrer, Carola Doerries, Meliana Riwanto, Diana M. Shih, Angeliki Chroni, Keiko Yonekawa, Sokrates Stein, Nicola Schaefer, Maja Mueller, Alexander Akhmedov, Georgios Daniil, Costantina Manes, Christian Templin, Christophe Wyss, Willibald Maier, Felix C. Tanner, Christian M. Matter, Roberto Corti, Clement Furlong, Aldons J. Lusis, Arnold Von Eckardstein, Alan M. Fogelman, Thomas F. Lüscher, Ulf Landmesser. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. Journal of Clinical Investigation, 2011; DOI: 10.1172/JCI42946
- Chieko Mineo, Philip W. Shaul. PON-dering differences in HDL function in coronary artery disease. Journal of Clinical Investigation, 2011; DOI: 10.1172/JCI57671
Cite This Page: